Biogen Idec Ma Inc.

Genetics Institute, Inc.

USA As Represented by Secretary of the Navy

University of Michigan

Aleta Biotherapeutics Inc.

Other

Dana-farber-cancer Institute Inc.

Repligen Corporation

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Minnesota

Biogen, Incorporated

Apoxis S.a.

Paul David Rennert

Gary S Gray

Carl H June

Gary J Nabel

Craig B Thompson

Roy R Lobb

Jeffrey L Browning

Paula S Hochman

Gordon James Freeman

Cindy L Jellis

Lee M Nadler

Christine Ambrose

Edward Alvin Greenfield

Jeffrey Thompson

Fabienne MacKay

Kashi Javaherian

John G Gribben

Fabienne Mackay

Jerry Carson

Sandra Silver

Alexey Alexandrovich Lugovskoy

John T Schiller

Pascal Schneider

Veronique Bailly

Benjamin Joseph Hackel

Teresa G Cachero

Patricia McCoon

Justin Klesmith

Jeffrey S Thompson

CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.

CD19 variants

Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.

Compositions and methods for treatment of cancer

Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.

Targeted cancer therapy

The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.

Compositions and methods for tumor transduction

The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.

Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders

Compositions and methods comprising 'lymphotoxin-&#x3b2; receptor blocking agents' which block lymphotoxin-&#x3b2; receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases

Compositions and methods for treating Th2- and ThI-mediated disease are provided.

KIM-1 antibodies for treatment of TH2-mediated conditions

Compositions and methods comprising 'lymphotoxin-&#x3b2; receptor blocking agents' which block lymphotoxin-&#x3b2; receptor signaling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.

The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-&#x3b3; by lymphocytes or other immune cells in a mammal. Inhibition of IFN-&#x3b3; is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.

KIM-1 antagonists and use to modulate immune system

Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed. Methods for inducing T cell apoptosis in vitro with an anti-CTLA4 antibody or other ligand of the invention together with an antigen specific signal are also disclosed, e.g., for use in purging alloreactive T cells from donor bone marrow prior to bone marrow transplantation to inhibit graft versus host disease.

Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies

Growing community of inventors

Holliston, MA, United States of America

Paul David Rennert